Dipeptidyl peptidase 4 (DPPIV, also known as CD26) is an approximately 110 kDa serine exopeptidase that releases Xaa-Pro or Xaa-Ala dipeptides from the N-terminus of oligo- and polypeptides. DPPIV is expressed as a noncovalent homodimer on the surface of epithelial cells, endothelial cells, and activated lymphocytes, and it can be released by MMP mediated shedding. It regulates immune and endocrine function through the cleavage of multiple chemokines, growth factors, and peptide hormones. It cleaves a range of peptide hormones including Glucagon, Glucagon-like Peptides 1 and 2, GIP, GHRH, Procalcitonin, Neuropeptide Y, and Substance P. It is released from adipocytes and induces insulin resistance in adipocytes and skeletal muscle. DPPIV also cleaves many chemokines, resulting in altered chemotactic activity or impacting chemokine blockade of HIV-1 cellular infectivity depending on the chemokine target. It cleaves human GM-CSF and IL-3 and reduces their ability to promote myeloid cell development. DPPIV inhibitors are approved for therapeutic treatment in type 2 diabetes and are being explored for treatment of several additional conditions including autoimmune diseases.

高纯度、高活性、低内毒素、高批间一致性

产品数据

-25 ~ -15℃保存，收到货之后有效期1年。 复溶后， 无菌条件下，-85 ~ -65℃保存，3个月有效期。